Clinical Trials Logo

Motion Sickness clinical trials

View clinical trials related to Motion Sickness.

Filter by:

NCT ID: NCT05640258 Completed - Seasickness Clinical Trials

Seasickness Susceptability and Vestibular Time Constant

Start date: September 18, 2017
Phase: N/A
Study type: Interventional

Participants were selected from the military navy crewmembers prior to commencing of active sailing. A vestibular time constant was calculated based on velocity step testing on a rotatory chair at baseline, 3 months and 6 month following active sailing duty. A seasickness questionnaire (WIKER) was completed during follow-up visits. study participants were divided to three groups based on WIKER score - susceptible , non-susceptible and habituating. Vestibular time constant was compared between study groups.

NCT ID: NCT05628220 Recruiting - Motion Sickness Clinical Trials

Motion Sickness Desensitization Using VR

SENSORIEL1
Start date: January 10, 2018
Phase: N/A
Study type: Interventional

Evaluation of a virtual reality desensitization protocol on subjects with severe motion sickness and study of the role of the emotional component on the effectiveness of the therapy.

NCT ID: NCT05622344 Recruiting - Vestibular Disorder Clinical Trials

StableEyes With Active Neurofeedback

SWAN
Start date: August 8, 2022
Phase: N/A
Study type: Interventional

The investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.

NCT ID: NCT05611814 Completed - Motion Sickness Clinical Trials

Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms

Start date: September 24, 2022
Phase: N/A
Study type: Interventional

Motion sickness directly impacts the readiness of the Army's aviation units. Severe motion sickness results in the dismissal of pilot and air crew candidates during initial training, while minor to moderate symptoms can be distracting during flight. The current medications on the market that target motion sickness symptoms are prohibited for use before flight. Osteopathic Manipulative Techniques are a low to no cost option, which lacks side effects, that allows Doctor of Osteopathic Medicine flight surgeons the opportunity to treat crew members without the use of pharmaceuticals. If effective, these techniques could be used to ensure aircrew readiness. Given the paucity of research on such a technique, a small, pilot study was conducted to demonstrate potential for such an approach.

NCT ID: NCT05548270 Completed - Motion Sickness Clinical Trials

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Start date: August 23, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating DPI-386 Nasal Gel versus placebo. Approximately 500 subjects will be randomized 1:1 (250 DPI 386 Nasal Gel/250 matching Placebo Nasal Gel) are planned to be enrolled.

NCT ID: NCT05004818 Completed - Motion Sickness Clinical Trials

Galvanic Vestibular Stimulation as a Novel Treatment for Seasickness

Start date: August 1, 2016
Phase: N/A
Study type: Interventional

subjects with severe seasickness, who failed to habituate to sea conditions after at least six month of active sailing, were enrolled to the single-blind randomized control study. The intervention group was treated with rotatory chair stimulation at sinusoidal harmonic acceleration protocol coupled with galvanic vestibular stimulation to the mastoid processes. This unique procedure was hypothesized to promote habituation to seasickness. The control group underwent a sham procedure. All study participants filled out seasickness questionnaires at set time points following the intervention and underwent repeated step testing to determine their vestibular time constant. The number of anti-motion sickness clinic visits and scopolamine prescriptions was also recorded in the three months period following the intervention.

NCT ID: NCT04999449 Recruiting - Motion Sickness Clinical Trials

Nebulizer Delivery of Intranasal Scopolamine

Start date: January 24, 2022
Phase: Phase 1
Study type: Interventional

To develop a better way to administer anti-motion sickness medications using an intranasal nebulizer.

NCT ID: NCT04947423 Completed - Motion Sickness Clinical Trials

Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Start date: June 14, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion

NCT ID: NCT04859868 Completed - Healthy Clinical Trials

Non-pharmaceutical Motion Sickness Mitigation

Start date: March 12, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is evaluate the effect of timing and magnitude on the administration of our nonpharmaceutical treatment to motion sickness, and to evaluate the effect of Galvanic Vestibular Stimulation (GVR) amplitude on functional fitness task performance.

NCT ID: NCT04482985 Not yet recruiting - Seasickness Clinical Trials

Meclizine Plasma Levels in Responders and Non-responders

Start date: September 1, 2020
Phase: Phase 4
Study type: Interventional

Motion sickness is a debilitating condition that can effect many crew members. Meclizine has long been known as an effective anti motion sickness drug. The response to the drug is variable - some are responders, while others are resistant to the drug. The aim of the present study is to examine whether there is a correlation between meclizine plasma levels and clinical response.